|
|
|
Volumn 28, Issue 10, 2003, Pages 991-1020
|
|
Annual Update 2003: Endocrine and Metabolic Drugs
a
a
PROUS SCIENCE
(Spain)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1426;
1954;
2 [1,2,3,4 TETRAHYDRO 2 [2 HYDROXY 2 [4 HYDROXY 3 (2 HYDROXYETHYL)PHENYL]ETHYLAMINO] 7 NAPHTHYLOXY] N,N DIMETHYLACETAMIDE;
2,2 DICHLORO 12 (4 CHLOROPHENYL)DODECANOIC ACID;
2BETA (3 HYDROXYPROPOXY)CALCITRIOL;
3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE;
5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE;
6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID;
7 [3 HYDROXY 2 [3 HYDROXY 4 (3 METHOXYMETHYLPHENYL) 1 BUTENYL] 5 OXOCYCLOPENTYL] 5 THIAHEPTANOIC ACID METHYL ESTER;
ABARELIX;
AERODOSE INSULIN;
AL 401;
AOD 9604;
AT 1391;
ATL 962;
AVR 118;
BALICATIB;
BARUSIBAN;
BIM 51077;
BIO T GEL;
BISPHOSPHONIC ACID DERIVATIVE;
BVT 3498;
CELECOXIB;
CHRYSALIN;
CINACALCET;
CP 533536;
CS 917;
DENOSUMAB;
DIAPEP 277;
DIENOGEST;
DISTRONTIUM RANELATE;
DROSPIRENONE PLUS ESTRADIOL;
E2CDS;
EG 006;
EML 4156;
ESTRADIOL;
ETHINYLESTRADIOL PLUS ETONOGESTREL;
ETHINYLESTRADIOL PLUS LEVONORGESTREL;
ETHINYLESTRADIOL PLUS NORELGESTROMIN;
ETIDRONIC ACID;
ETORICOXIB;
FK 614;
FORTICAL;
GI 181771;
GLIPIZIDE PLUS METFORMIN;
GW 677954;
GW 869682;
HF 0299;
HOE 21PH;
HORMONE ANALOG;
HUMAN GROWTH HORMONE;
HYDROCORTISONE;
IMIGLITAZAR;
INSULIN;
INSULIN ASPART;
IOGEN;
ISIS 113715;
KI 02 012;
L 796568;
LARONIDASE;
LGD 2226;
LIBIGEL ET;
LIRAGLUTIDE;
LUMIRACOXIB;
LY 307161;
LY 510929;
MB 6322;
MECASERMIN RINFABATE;
METAGLIDASEN;
METFORMIN;
METFORMIN GR;
METFORMIN PLUS ROSIGLITAZONE;
MIGLUSTAT;
MINODRONIC ACID;
MITIGLINIDE;
N 0767;
N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE;
NATEGLINIDE;
NAVEGLITAZAR;
NBI 42902;
NBI 6024;
NETOGLITAZONE;
NITISINONE;
NN 2501;
NN 344;
NN 414;
NOX 700;
OGT 923;
ONO 8815LY;
ORAL ANTIDIABETIC AGENT;
ORAL CONTRACEPTIVE AGENT;
ORG 33628;
ORG 43553;
P 57;
P 93 01;
PARATHYROID HORMONE[1-34];
PASIREOTIDE;
PEGVISOMANT;
PRAMLINTIDE;
PRASTERONE;
PROSTAGLANDIN E1;
R 1164;
R 1438;
R 1439;
R 483;
R 765;
RAMIPRIL;
RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;
RECOMBINANT CILIARY NEUROTROPHIC FACTOR;
RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;
RECOMBINANT HUMAN INSULIN;
RECOMBINANT PARATHYROID HORMONE;
RECOMBINANT SOMATOMEDIN C;
RELACATIB;
RETICULOSE;
RG 228;
S 15261;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
SERM 3471;
SMP 140;
SOLABEGRON;
SOMATOMEDIN BINDING PROTEIN 3;
SR 146131;
SSR 125180;
ST 1326;
SUFUGOLIX;
T 131;
TANAPROGET;
TAU;
TESTOSTERONE;
TETRAHYDROLIPSTATIN;
TH 9507;
THYROTROPIN;
TP 508;
TRX 4;
TT 235;
TX 525;
UK 390957;
ULINASTATIN;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VALDECOXIB;
VAPREOTIDE;
VILDAGLIPTIN;
YM 178;
ZP 10;
ADDISON DISEASE;
ADRENAL CORTEX INSUFFICIENCY;
CLINICAL TRIAL;
DIABETES MELLITUS;
ENDOCRINE DISEASE;
GENITAL SYSTEM DISEASE;
GROWTH PROMOTING SIDE EFFECT;
GYNECOLOGIC DISEASE;
HUMAN;
HYPERPARATHYROIDISM;
HYPOPHYSIS DISEASE;
MITOGENICITY;
PUBLICATION;
REVIEW;
SEXUAL DYSFUNCTION;
SIDE EFFECT;
THYROID DISEASE;
|
|
EID: 0347364789
PISSN: 03778282
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (5)
|
|
References (7)
|
